But unfortunately, residual Retinoblastoma cells became resistant to these CAR-GD2 T cells by selective attenuated expression of GD2, and increased PD-L1 expression on tumor cells, suggesting a combinatorial approach along with the genetically modified T cells to achieve a more pronounced antitumor effect in Retinoblastoma. The gene discussed is CD274; the disease is retinoblastoma.